Week Ending August 23, 2021

Optellum Announces Strategic Collaboration With The Lung Cancer Initiative At Johnson & Johnson, Applying AI To Transform Early Lung Cancer Treatmen
“OXFORD, United Kingdom and HOUSTON, Aug. 18, 2021 /PRNewswire/ — Optellum, a lung-health AI company, has entered a strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson*. Through the collaboration, Optellum will apply its AI-powered clinical decision support platform with the goal of increasing lung cancer survival rates through early intervention and prevention.”

Medicare-Insured Patients With Advanced Lung Cancer Have Worse Survival
“Older patients with advanced non-small cell lung cancer (NSCLC) who are Medicare-insured tend to have shorter overall survival (OS) compared with patients observed in registrational clinical trials, according to recent research.”

KRAS Inhibitors Meet New Turning Point in Non-Small Cell Lung Cancer
“KRAS G12C inhibitors have developed greatly over recent years, expanding the number of effective targeted therapies in non-small cell lung cancer (NSCLC). Researchers expect that efforts to assess predictive co-mutations, acquired resistance, and combination strategies will continue to advance the effectiveness of these agents even more, explained Karen L. Reckamp, MD.”

Med News: Biomarkers and what they mean for lung cancer treatments
“Biomarker testing and targeted treatments have contributed to improved outcomes for people with lung cancer. However, not enough people are undergoing comprehensive biomarker testing.”

Radiologist-delivered ablation for lung cancer costs significantly less than surgery, but utilization still low
“Imaging-guided, radiologist-delivered ablation to treat lung cancer costs significantly less than surgery, but utilization remains uniformly low, experts charged in a new study published Saturday.”

Oncocyte Launches First Real-World Evidence (RWE) Registry to Evaluate Biomarker Impact on Early-Stage Lung Cancer Treatment Decisions and Outcomes
“Predictive Assay for Decision Making in Adjuvant Therapy (PADMA) Registry to enroll more than 1,000 patients at 25 major hospitals treating lung cancer in the United States beginning Q4 2021”